Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Allergan_Aesthetics
|
| gptkbp:acquisition |
Medytox USA
|
| gptkbp:awards |
Korean Bio Award
Korea’s Best Company Award |
| gptkbp:ceo |
Dr. Jae-Ho Lee
|
| gptkbp:clinical_trial |
Phase III trials
therapeutic applications cosmetic applications Botulinum toxin for chronic migraine Botulinum toxin for cosmetic use Botulinum toxin for overactive bladder Botulinum toxin for spasticity neurotoxin efficacy |
| gptkbp:collaborations |
gptkb:Seoul_National_University
gptkb:Harvard_University |
| gptkbp:community_engagement |
health education programs
scholarship programs support for local charities |
| gptkbp:employees |
over 200
|
| gptkbp:founded |
gptkb:2000
|
| gptkbp:founder |
Dr. Jae-Ho Lee
|
| gptkbp:headquarters |
gptkb:Seongnam,_South_Korea
|
| https://www.w3.org/2000/01/rdf-schema#label |
Medytox
|
| gptkbp:industry |
gptkb:drug
|
| gptkbp:invention |
over 100 patents
|
| gptkbp:investment |
gptkb:Samsung_Venture_Investment
KTB Network Korea Investment Partners |
| gptkbp:market |
gptkb:China
gptkb:Monarch gptkb:United_States 5% in China 20% in South Korea 3% in the USA Innotox in 2012 Medytox A in 2018 Neuronox in 2006 |
| gptkbp:partnership |
gptkb:Allergan
Medytox and Allergan Medytox and Galderma Medytox and Ipsen |
| gptkbp:products |
Innotox
Medytox A Neuronox |
| gptkbp:regulatory_compliance |
gptkb:FDA
gptkb:EMA KFDA |
| gptkbp:research_focus |
neurotoxin research
|
| gptkbp:revenue |
$50 million (2020)
|
| gptkbp:specializes_in |
botulinum toxin products
|
| gptkbp:stock_exchange |
gptkb:KOSDAQ
|
| gptkbp:subsidiary |
Medytox Europe
Medytox USA |
| gptkbp:sustainability_initiatives |
energy efficiency measures
waste reduction programs green manufacturing practices |
| gptkbp:website |
www.medytox.com
|